You just read:

ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

News provided by

CStone Pharmaceuticals

Nov 06, 2019, 21:41 ET